Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/a-comparison-of-single-and-double-chain-recombinant-tissue-plasminogen-iYwVtNt7Os
References (7)
-
G. Timmis (1988)
EDITORIAL REVIEW.: In Search of The Ideal Thrombolytic AgentJournal of Interventional Cardiology, 1
-
P. Armstrong, P. Armstrong, R. Baigrie, R. Baigrie, P. Daly, P. Daly, A. Haq, A. Haq, M. Gent, M. Gent, Robin Roberts, R. Roberts, M. Freeman, M. Freeman, R. Burns, R. Burns, P. Liu, Peter Liu, C. Morgan, C. Morgan (1989)
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction.Journal of the American College of Cardiology, 13 7
-
Jeffrey Anderson (1988)
Anistreplase (APSAC) and Future Trends in Thrombolytic TherapyJournal of Interventional Cardiology, 1
-
Kurnik Kurnik, DeWood DeWood (1988)
the Burroughs Wellcome t‐PA Study Group (1988). A dose response, multicenter trial with a new tissue plasminogen activator (t‐PA) preparation in patients with pretreatment angiographyCirculation, 78
-
P. Sleight (1988)
Thrombolysis in Acute Myocardial Infaction: Lessons from ISIS‐2Journal of Interventional Cardiology, 1
-
E. Topol, B. George, D. Kereiakes, R. Candela, C. Abbottsmith, D. Stump, J. Boswick, R. Stack, R. Califf (1988)
Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction.The American journal of cardiology, 61 10
-
Timmis Timmis (1988)
In search of the ideal thrombolytic agent (Editorial Review)J Interven Cardiol, 1
- Publisher
- Wiley
- Copyright
- Copyright © 1989 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0896-4327
- eISSN
- 1540-8183
- DOI
- 10.1111/j.1540-8183.1989.tb00756.x
- Publisher site
- See Article on Publisher Site
Abstract
Is2 the editorial review that immediately follows. R e p resentatives of the Burroughs Wellcome Company felt that while they have archived a multitude of data, too few peer-reviewed publications are currently in print to support a referenced editorial review authored by their own people. When such publications codifying the performance of Wellcome t-PA are available, another invitation will be extended to the Burroughs Wellcome Company by your editors for this purpose. These comparisons become particularly critical since the use of the predominantly double-chain form of t-PA (Wellcome) will be employed in ISIS-3. This international trial, which will begin in the United Kingdom, the United States and elsewhere in early fall, will compare the double-chain species of t-PA administered intravenously, to similarly infused streptokinase and anistreplase’ in a total group of approximately 30,000 patient^.^" Gerald C. Timmis, M.D.
Journal
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 1989